Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 6/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.74 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11121205 | 0.94 | PDE5A (0.91) | PDE5ANR3C2PTGS2ATMRXFP1 | |
| SCHEMBL11119541 | 0.94 | PDE5A (0.91) | PDE5ANR3C2PTGS2ATMRXFP1 | |
| SCHEMBL11121023 | 0.94 | PDE5A (0.91) | PDE5ANR3C2PTGS2ATMRXFP1 | |
| SCHEMBL12493661 | 0.90 | PDE5A (1.00) | PDE5ANR3C2PTGS2ATMRXFP1 | |
| SCHEMBL12494300 | 0.85 | PDE5A (1.00) | PDE5ANR3C2PTGS2ATMRXFP1 | |
| SCHEMBL12496095 | 0.84 | PDE5A (1.00) | PDE5ANR3C2PTGS2ATMRXFP1 | |
| SCHEMBL12495092 | 0.82 | PDE5A (1.00) | PDE5ANR3C2PTGS2ATMRXFP1 | |
| SCHEMBL11122272 | 0.81 | PDE5A (0.83) | PDE5ANR3C2PTGS2ATMGLA | |
| SCHEMBL11126048 | 0.81 | PDE5A (0.83) | PDE5ANR3C2PTGS2ATMGLA | |
| SCHEMBL10362296 | 0.80 | EGFR (0.81) | PDE5ANR3C2ATMRXFP1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388139-B2 | Derivatives of celeboxib, use thereof and preparation thereof | GERMAN UNIVERSITY (EG) | 2016-07-12 | — | — | US | disclosed |
| US-9388139-B2 | Derivatives of celeboxib, use thereof and preparation thereof | GERMAN UNIVERSITY (EG) | 2016-07-12 | — | — | US | disclosed |
| US-20140171477-A1 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2014-06-19 | — | — | US | disclosed |
| US-20140171477-A1 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2014-06-19 | — | — | US | disclosed |
| WO-2012125884-A1 | DERIVATIVES OF CELECOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125884-A1 | DERIVATIVES OF CELECOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171477-A1 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | PDE5A, PDE3A, PDE3B | PDE5A 1/4885NR3C2 373/4885PTGS2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.